Leerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7

MannKind Corporation (NASDAQ:MNKD) is one of the top strong buy stocks under $5 to buy now. On August 8, Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on MannKind Corporation (NASDAQ:MNKD), keeping the price target at $7.00.

Similarly, in a report released on August 7, Douglas Miehm from RBC Capital maintained a Buy rating on MannKind Corporation (NASDAQ:MNKD) with a price target of $7.00.

The same day, Mizuho Securities also released a report maintaining a Buy rating on the stock with a $10.00 price target.

Currently, the analyst consensus on MannKind Corporation (NASDAQ:MNKD) is a Strong Buy. The stock’s median price target of $4.11 implies an upside of 118.98% from current levels.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that develops and commercializes innovative therapeutic devices and products that address serious unmet medical needs for endocrine and orphan lung diseases.

The company’s pipeline and products include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.